Orgenesis Inc (NASDAQ:ORGS) — Market Cap & Net Worth

$9.83 Million USD  · Rank #26924

Market Cap & Net Worth: Orgenesis Inc (ORGS)

Orgenesis Inc (NASDAQ:ORGS) has a market capitalization of $9.83 Million ($9.83 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26924 globally and #5351 in its home market, demonstrating a 2.58% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orgenesis Inc's stock price $1.95 by its total outstanding shares 5171310 (5.17 Million). Analyse ORGS operating cash flow to see how efficiently the company converts income to cash.

Orgenesis Inc Market Cap History: 2025 to 2025

Orgenesis Inc's market capitalization history from 2025 to 2025. Data shows growth from $10.08 Million to $10.08 Million (0.00% CAGR).

Orgenesis Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Orgenesis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

No P/S ratio data available

Latest Price to Earnings (P/E) Ratio

No P/E ratio data available

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
No financial ratio data available

Competitor Companies of ORGS by Market Capitalization

Companies near Orgenesis Inc in the global market cap rankings as of May 4, 2026.

Key companies related to Orgenesis Inc by market ranking:

  • Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
  • Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
  • UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
  • argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#223 Vertex Pharmaceuticals Inc NASDAQ:VRTX $107.56 Billion $423.92
#367 Regeneron Pharmaceuticals Inc NASDAQ:REGN $72.88 Billion $701.42
#517 UCB SA BR:UCB $51.45 Billion €231.20
#568 argenx NV ADR NASDAQ:ARGX $45.97 Billion $787.95

Orgenesis Inc Historical Marketcap From 2025 to 2025

Between 2025 and today, Orgenesis Inc's market cap moved from $10.08 Million to $ 10.08 Million, with a yearly change of 0.00%.

Year Market Cap Change (%)
2025 $10.08 Million --

End of Day Market Cap According to Different Sources

On May 4th, 2026 the market cap of Orgenesis Inc was reported to be:

Source Market Cap
Yahoo Finance $9.83 Million USD
MoneyControl $9.83 Million USD
MarketWatch $9.83 Million USD
marketcap.company $9.83 Million USD
Reuters $9.83 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Orgenesis Inc

NASDAQ:ORGS USA Biotechnology
Market Cap
$10.08 Million
Market Cap Rank
#26924 Global
#5351 in USA
Share Price
$1.95
Change (1 day)
+0.08%
52-Week Range
$1.90 - $2.09
All Time High
$2.09
About

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of res… Read more